Conformis, Inc. (NASDAQ:CFMS) CEO Sells $10,302.16 in Stock

Conformis, Inc. (NASDAQ:CFMSGet Rating) CEO Mark A. Augusti sold 22,396 shares of the business’s stock in a transaction that occurred on Saturday, May 7th. The stock was sold at an average price of $0.46, for a total transaction of $10,302.16. Following the completion of the sale, the chief executive officer now owns 2,433,726 shares of the company’s stock, valued at $1,119,513.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Shares of NASDAQ CFMS opened at $0.40 on Wednesday. The company has a quick ratio of 6.22, a current ratio of 6.84 and a debt-to-equity ratio of 0.24. Conformis, Inc. has a 52 week low of $0.40 and a 52 week high of $1.96. The firm’s fifty day moving average is $0.61 and its 200 day moving average is $0.74. The company has a market cap of $74.91 million, a price-to-earnings ratio of -10.10 and a beta of 1.42.

Conformis (NASDAQ:CFMSGet Rating) last issued its earnings results on Wednesday, May 4th. The medical instruments supplier reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.02). Conformis had a negative return on equity of 6.50% and a negative net margin of 6.83%. During the same quarter in the previous year, the company earned ($0.09) earnings per share. Equities research analysts anticipate that Conformis, Inc. will post -0.31 earnings per share for the current year.

A number of brokerages have recently weighed in on CFMS. Zacks Investment Research upgraded shares of Conformis from a “strong sell” rating to a “hold” rating in a report on Wednesday, May 4th. StockNews.com began coverage on shares of Conformis in a report on Thursday, March 31st. They issued a “hold” rating for the company.

A number of institutional investors have recently modified their holdings of CFMS. Morgan Stanley increased its position in Conformis by 657.6% during the 1st quarter. Morgan Stanley now owns 29,283 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 25,418 shares during the period. Lake Street Financial LLC purchased a new position in Conformis during the 4th quarter valued at $31,000. Commonwealth Equity Services LLC increased its position in Conformis by 116.3% during the 3rd quarter. Commonwealth Equity Services LLC now owns 27,901 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 15,000 shares during the period. Royal Bank of Canada purchased a new position in Conformis during the 3rd quarter valued at $39,000. Finally, Citadel Advisors LLC purchased a new position in Conformis during the 3rd quarter valued at $52,000. 51.01% of the stock is currently owned by institutional investors and hedge funds.

About Conformis (Get Rating)

Conformis, Inc, a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, a custom-made partial knee replacement option for either unicompartmental or bicompartmental osteoarthritis of the knee; iTotal CR, a cruciate retaining total knee replacement product; iTotal PS, a posterior stabilized knee replacement product, as well as provides iTotal Identity and Identity Imprint knee replacement products.

Further Reading

Insider Buying and Selling by Quarter for Conformis (NASDAQ:CFMS)

Receive News & Ratings for Conformis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conformis and related companies with MarketBeat.com's FREE daily email newsletter.